XML 31 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
STATEMENTS OF CASH FLOWS (USD $)
 9 Months Ended
Jun. 30, 2013
Jun. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (7,471,090) $ (12,910,618)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 302,871 391,571
Issuance of common stock, warrants and options for services 364,318 402,708
Extension of stock options issued to consultants 0 54,789
Extension of options issued to employees 0 36,990
Employee option cost 2,087,718 1,724,375
Common stock contributed to 401 (k) plan 119,190 115,693
Impairment loss on abandonment of patents 10,651 37,352
Loss on retired equipment 4,199 9,016
Gain on derivative instruments (7,363,854) (142,532)
(Increase)/decrease in assets:    
Receivables (5,125) 431,684
Deferred rent 409,400 450,374
Prepaid expenses 529,511 406,305
Inventory used for R&D and manufacturing 248,892 198,648
Deposits (400,000) 0
Increase/(decrease) in liabilities:    
Accounts payable 560,521 (36,259)
Accrued expenses 392,311 (96,513)
Due to employees 67,752 3,443
Deferred rent liability 640 (3,880)
Deferred revenue 45 1,500
Deposits held 0 5,000
Net cash used in operating activities (10,142,050) (8,920,354)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of equipment (93,419) (43,222)
Expenditures for patent costs (24,446) (78,959)
Net cash used in investing activities (117,865) (122,181)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock 9,807,375 14,289,518
Proceeds from exercise of warrants and stock options 0 2,664,539
Payments on convertible debt 0 (4,950,000)
Payments on oblgations under capital leases (4,432) 0
Net cash provided by financing activities 9,802,943 12,004,057
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (456,972) 2,961,522
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 3,941,042 4,260,594
CASH AND CASH EQUIVALENTS, END OF PERIOD 3,484,070 7,222,116
ISSUANCE OF WARRANTS:    
Increase in derivative liabilities (4,200,000) (6,706,667)
Decrease in additional paid-in capital 4,200,000 6,706,667
Total 0 0
ISSUANCE OF ADDITIONAL SHARES    
Increase in common stock 0 (8,333)
Increase in additional paid-in capital 0 (241,667)
Decrease in additional paid-in capital 0 250,000
Total 0 0
EXERCISE OF DERIVATIVE LIABILITIES:    
Decrease in derivative liabilities 0 122,367
Increase in additional paid-in capital 0 (122,367)
Total 0 0
MODIFICATION OF WARRANTS:    
Increase additional paid-in capital (59,531) (325,620)
Decrease in additional paid-in capital 59,531 325,620
INDUCEMENT WARRANTS:    
Increase in additional paid-in capital 0 (1,593,000)
Decrease in additional paid-in capital 0 1,593,000
Total 0 0
ISSUANCE OF COMMON STOCK FOR PREPAID SERVICES:    
Increase in additional paid-in capital (117,090) (141,333)
Increase in prepaid expenses 117,090 141,333
Total 0 0
PATENT COSTS INCLUDED IN ACCOUNTS PAYABLE    
Increase in patent costs 13,145 0
Increase in accounts payable (13,145) 0
Total 0 0
NON CASH RESEARCH AND OFFICE EQUIPMENT PURCHASES    
Increase in research and office equipment 45,236 0
Increase in accounts payable (8,614) 0
Increase in capital lease obligation (36,622) 0
Total 0 0
CAPITAL LEASE PAYMENTS INCLUDED IN ACCOUNTS PAYABLE:    
Decrease in capital lease obligation 1,197 0
Increase in accounts payable (1,197) 0
Total 0 0
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:    
Cash expenditures for interest expense $ 126,950 $ 336,316